Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 28373364)

  • 1. Strategies for Increasing Pancreatic Tumor Immunogenicity.
    Johnson BA; Yarchoan M; Lee V; Laheru DA; Jaffee EM
    Clin Cancer Res; 2017 Apr; 23(7):1656-1669. PubMed ID: 28373364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and Emerging Therapies in Metastatic Pancreatic Cancer.
    Manji GA; Olive KP; Saenger YM; Oberstein P
    Clin Cancer Res; 2017 Apr; 23(7):1670-1678. PubMed ID: 28373365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.
    Haqq J; Howells LM; Garcea G; Metcalfe MS; Steward WP; Dennison AR
    Eur J Cancer; 2014 Oct; 50(15):2570-82. PubMed ID: 25091797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer.
    Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S
    Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
    Lafaro KJ; Melstrom LG
    Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Immune Microenvironment in Pancreatic Cancer.
    Huber M; Brehm CU; Gress TM; Buchholz M; Alashkar Alhamwe B; von Strandmann EP; Slater EP; Bartsch JW; Bauer C; Lauth M
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33022971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma".
    Borazanci E; Dang CV; Robey RW; Bates SE; Chabot JA; Von Hoff DD
    Clin Cancer Res; 2017 Apr; 23(7):1629-1637. PubMed ID: 28373361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked.
    Evan GI; Hah N; Littlewood TD; Sodir NM; Campos T; Downes M; Evans RM
    Clin Cancer Res; 2017 Apr; 23(7):1647-1655. PubMed ID: 28373363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
    Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma.
    Tang D; Wang D; Yuan Z; Xue X; Zhang Y; An Y; Chen J; Tu M; Lu Z; Wei J; Jiang K; Miao Y
    Int J Cancer; 2013 Mar; 132(5):993-1003. PubMed ID: 22777597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.
    Ahmad RS; Eubank TD; Lukomski S; Boone BA
    Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34204306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of pancreatic cancer therapy resistance by chemokines.
    Gautam SK; Basu S; Aithal A; Dwivedi NV; Gulati M; Jain M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):69-80. PubMed ID: 36064086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma.
    Seifert AM; List J; Heiduk M; Decker R; von Renesse J; Meinecke AC; Aust DE; Welsch T; Weitz J; Seifert L
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3233-3240. PubMed ID: 32865617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
    Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
    Front Immunol; 2021; 12():719105. PubMed ID: 35111149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Status of Immunotherapies for Treating Pancreatic Cancer.
    Wu AA; Jaffee E; Lee V
    Curr Oncol Rep; 2019 May; 21(7):60. PubMed ID: 31101991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.